IRCT20220104053626N4招募中2 期
comparison of the effectiveness and patient tolerance of oral lavage of Rhamnus frangula extract and polyethylene glycol for colonoscopy preparation. A randomized controlled trial study
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 116
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 75 years（—）
- 性别
- All
入选标准
- •willingness to participate
排除标准
- •any history of drug reaction
- •history of disphagia and swallowing dysfunction
- •history of ileus and bowel obstruction and gastroparesia
- •active inflammatory bowel disease
- •electrolyte imbalance
- •renal and liver failure
- •pregnancy and lactation
研究者
相似试验
已完成
不适用
Comparison of the Clinical Efficacy and Tolerability of Latanoprost RDR Eye Drops vs. Xalatan® Eye Drops for the Treatment of Ocular Hypertension and Primary Open Angle GlaucomaPrimary Open Angle GlaucomaEye DiseasesGlaucomaOcular HypertensionISRCTN80385690RDR Pharma GmbH (Germany)260
进行中（未招募）
不适用
Comparison of the Clinical Efficacy and Tolerability of Latanoprost RDR 0.005% Eye Drops Test Formulation of RDR Pharma GmbH, Germany, for the Treatment of Ocular Hypertension and Primary Open Angle Glaucoma, with Xalatan® 0.005% Eye DropsOcular Hypertension (IOP>22 mmHg), Primary Open Angle Glaucoma (mean defect between 0 and -12 db in a visual field)MedDRA version: 9.1Level: LLTClassification code 10030043Term: Ocular hypertensionMedDRA version: 9.1Level: LLTClassification code 10036719Term: Primary open angle glaucomaEUCTR2008-002122-10-BGRDR Pharma GmbH300
进行中（未招募）
不适用
Comparison of the Clinical Efficacy and Tolerability of Latanoprost RDR 0.005% Eye Drops Test Formulation of RDR Pharma GmbH, Germany, for the Treatment of Ocular Hypertension and Primary Open Angle Glaucoma, with Xalatan® 0.005% Eye Drops. A multicenter, randomized, investigator-blind, clinical trial with parallel groupsOcular Hypertension (IOP>22 mmHg), Primary Open Angle Glaucoma (mean defect between 0 and -12 db in a visual field)MedDRA version: 9.1Level: LLTClassification code 10030043Term: Ocular hypertensionMedDRA version: 9.1Level: LLTClassification code 10036719Term: Primary open angle glaucomaEUCTR2008-002122-10-LVRDR Pharma GmbH260
进行中（未招募）
不适用
Comparison of the Clinical Efficacy and Tolerability of Latanoprost RDR 0.005% Eye Drops Test Formulation of RDR Pharma GmbH, Germany, for the Treatment of Ocular Hypertension and Primary Open Angle Glaucoma, with Xalatan® 0.005% Eye Drops. A multicenter, randomized, investigator-blind, clinical trial with parallel groupsEUCTR2008-002122-10-LTRDR Pharma GmbH260
进行中（未招募）
不适用
Comparison of the Clinical Efficacy and Tolerability of Latanoprost RDR 0.005% Eye Drops Test Formulation of RDR Pharma GmbH, Germany, for the Treatment of Ocular Hypertension and Primary Open Angle Glaucoma, with Xalatan® 0.005% Eye Drops. A multicenter, randomized, investigator-blind, clinical trial with parallel groupsOcular Hypertension (IOP>22 mmHg), Primary Open Angle Glaucoma (mean defect between 0 and -12 db in a visual field)MedDRA version: 9.1Level: LLTClassification code 10030043Term: Ocular hypertensionMedDRA version: 9.1Level: LLTClassification code 10036719Term: Primary open angle glaucomaEUCTR2008-002122-10-DERDR Pharma GmbH260